Skip to main content

Table 2 Cox univariate and multivariate analysis of RFS, BCSS and OS in cohort 2 (TMA), and also stratified into the ER-positive cohort

From: Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer

 

RFS

 

BCSS

 

OS

 
 

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

All patients (n = 432)

      

PRDX1 protein expression

Univariate

 

Univariate

 

Univariate

 

  Low

1

 

1

 

1

 

  High#

0.71 (0.50 - 1.02)

0.063

0.81 (0.62 - 1.04)

0.102

0.66 (0.42 - 1.04)

0.071

PRDX1 protein expression

Multivariate*

 

Multivariate*

 

Multivariate*

 

  Low

1

 

1

 

1

 

  High#

0.78 (0.52 - 1.16)

0.218

0.76 (0.45 - 1.28)

0.302

0.76 (0.56 - 1.03)

0.076

ER + patients (n = 365)

      

PRDX1 protein expression

Univariate

 

Univariate

 

Univariate

 

  Low

1

 

1

 

1

 

  High#

0.60 (0.40 - 0.89)

0.012

0.69 (0.52 - 0.92)

0.010

0.44 (0.25 - 0.75)

0.003

PRDX1 protein expression

Multivariate*

 

Multivariate*

 

Multivariate*

 

  Low

1

 

1

 

1

 

  High#

0.62 (0.40 - 0.96)

0.032

0.44 (0.24 - 0.79)

0.006

0.61 (0.44 - 0.85)

0.004

  1. *Multivariate analysis included adjustment for tumor size, grade, age, nodal, ER, PR, Her2 and Ki67 status. PRDX1 protein expression levels stratified by the median. #PRDX1 protein expression levels are stratified by the median protein expression value. BCSS, breast cancer-specific survival; CI, confidence interval; ER, estrogen receptor; Her2, human epidermal growth factor receptor 2; HR, hazard ratio; OS, overall survival; PR, progesterone receptor; PRDX1, peroxiredoxin 1; RFS, recurrence-free survival; RPPA, reverse phase protein arrays.